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Abbreviations used 
AD  Atopic Dermatitis 
AZA  Azathioprine 
EASI  Eczema Area and Severity Index 
FLG  Filaggrin gene 
FMG  Filaggrin Mutation Group 
IGA  Investigator Global Assessment  
LRM  Linear Regression Model 
MTX  Methotrexate 
Non-FMG Non Filaggrin Mutation Group 
NMF   Natural Moisturizing Factors (NMF) 
OSI  Online Supporting Information 
PGA  Patient Global Assessment 
POEM  Patient Oriented Eczema Measurement 
SCORAD  SCOring Atopic Dermatitis 
SCORAD50 Improvement of SCORAD with at least 50% 
SD  Standard Deviation 
VAS  Visual Analogue Scale 
 
Research Letter;   
Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship 
between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate 
whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG 
mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with 
methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.(1) Two years after 
randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the 
FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations).  
 
In the original RCT both MTX and AZA induced significant reductions in SCORAD at 12 and 24 weeks, without a 
significant difference between treatments.(1) We therefore pooled all patients together for this sub-study and 
divided them into a FLG mutation group (FMG) and non-FMG. The primary outcome parameter was the 
SCORAD, which was obtained at baseline, week 2,4,8,12 and 24 and analysed as repeated measurements 
(lme4 package in R (version 3.2.5). All SCORAD values were obtained from patients receiving systemic 
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immunosuppressive treatment with or without topical immunosuppressive treatment, except for three values 
in three patients. Two patients stopped systemic treatment because of adverse events (FMG, week 2; non-
FMG, week 4) and their last scores, obtained within 2 weeks of stopping systemic therapy, were under topical 
immunosuppressive treatment alone. One patient (FMG) stopped systemic treatment at week 12, and values 
at week 24 were under topical immunosuppressive treatment alone.  As the mean age was significantly higher 
in the FMG vs. the non-FMG (P<0.01, online supporting information (OSI), Table E1), all analyses were 
corrected for age as a possible confounder and age was included in the models as a potential confounder 
variable. As treatment regimen (AZA or MTX) did not influence treatment success in FMG vs. non-FMG, we 
included in the mixed models as covariates visit, mutation, age and an interaction term for visit *mutation.  
 
The main limitation of this sub-study was the small sample size and the inability to randomize on FLG mutation 
status. For details see Methods section at the OSI (www.brjdermatol.org), and our previous publication.(1)  
 
FLG mutations were found in 13 patients (36%, OSI Tabel E2).  Every single patient, both in FMG and non-FMG, 
showed improvement of SCORAD at week 24 compared to baseline (OSI Figure E1). The mean SCORAD in the 
FMG decreased with 20.7 points (95%CI 14.7-26.6, P < 0.01) and 31.3 points in the non-FMG (95%CI 26.3-36.2, 
P < 0.01). However, in the course of 24 weeks, the FMG showed less improvement in SCORAD compared to the 
non-FMG (P=0.02) and the improvement in SCORAD of patients in the FMG stagnated during the course of the 
treatment (Figure 1). When the three SCORAD values obtained under topical treatment alone were excluded 
from data analysis, the FMG showed a trend towards less improvement in the course of 24 weeks compared to 
non-FMG , as a significant difference was not reached (P=0.075). Median dosages of topical 
immunosuppressive treatment (FMG 132 gram, non-FMG 120 gram, P=0.51) and median dosages of MTX 
(FMG 83.8 gram, non-FMG 90 gram, P=0.26) and AZA ( FMG 837.5 gram, non-FMG 825 gram P=0.75) were 
comparable between groups in the course of 24 weeks (Mann Whitney U test).  
 
It is interesting to speculate on mechanisms underlying lower response to immunosuppressive treatment in 
AD patients with a FLG mutation. Th2 cytokines can down-regulate filaggrin protein expression(3) and skin 
barrier impairment in AD patients with severe skin inflammation seems similar in patients with and without 
FLG mutations and correlated with the SCORAD.(4) As only patients with severe AD were included in our 
study(1), we expect that at initiation of the study levels of skin barrier impairment and inflammation were 
comparable in the FMG and non-FMG, which is supported by similar mean SCORAD in both groups. When 
decreasing inflammation by immunosuppressive treatment, downregulation of FLG expression by the 
inflammatory infiltrate will be abrogated, therefore allowing skin barrier restoration and likely establishment 
of normal filaggrin protein levels in the non-FMG. In contrast, FMG patients will also experience improvement 
of their AD due to the immunosuppression, but their barrier function impairment and reduced filaggrin protein 
levels will still be present in the end because of their genetically caused filaggrin protein deficiency. This may 
explain the  lower therapeutic responses in the FMG in the course over 24 weeks, and why the initial 
improvement stagnates during the treatment period. In conclusion, both groups showed a significant 
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improvement in SCORAD compared to baseline, however, FLG mutations may have a negative impact on 
immunosuppressive treatment success in severe AD as the improvement in the FMG stagnated during the 
course of the treatment. Additional research investigating the relationship between FLG mutation status and 
treatment success are necessary to confirm these findings.  
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Figure1. Mean (SD) reduction in SCORAD from baseline till 24 weeks, adjusted for age 
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Differences in outcomes between the filaggrin mutation group (FMG, n=13) and non-FMG (n=23) when on 
combined systemic and topical immunosuppressive treatment, or topical immunosuppressive treatment alone.  
Data includes all data points. Ggplot package in R was used to draw the Figures. The gray areas 
represents the 95% confidence interval for the mean reduction in SCORAD in the FMG and the non-FMG. Dark 
gray represents an overlap between groups.  These results show that both groups showed an improvement in 
SCORAD compared to baseline, however FMG patients showed less improvement in SCORAD in the course of 24 
weeks compared to non-FMG (P=0.02), and improvement stagnates during the course of the treatment.  
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